Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Carcinoma, Renal Cell 6Brenner Tumor 6Melanoma 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colonic Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Paclitaxel 2etoposide phosphate 1Taxes 1Platinum 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sertoli-Leydig Cell Tumor × Disulfides × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡